242 related articles for article (PubMed ID: 18621549)
1. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves.
Gupta V; Barzilla JE; Mendez JS; Stephens EH; Lee EL; Collard CD; Laucirica R; Weigel PH; Grande-Allen KJ
Cardiovasc Pathol; 2009; 18(4):191-7. PubMed ID: 18621549
[TBL] [Abstract][Full Text] [Related]
2. Differential proteoglycan and hyaluronan distribution in calcified aortic valves.
Stephens EH; Saltarrelli JG; Baggett LS; Nandi I; Kuo JJ; Davis AR; Olmsted-Davis EA; Reardon MJ; Morrisett JD; Grande-Allen KJ
Cardiovasc Pathol; 2011; 20(6):334-42. PubMed ID: 21185747
[TBL] [Abstract][Full Text] [Related]
3. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading.
Grande-Allen KJ; Calabro A; Gupta V; Wight TN; Hascall VC; Vesely I
Glycobiology; 2004 Jul; 14(7):621-33. PubMed ID: 15044391
[TBL] [Abstract][Full Text] [Related]
4. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion.
Kolodgie FD; Burke AP; Farb A; Weber DK; Kutys R; Wight TN; Virmani R
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1642-8. PubMed ID: 12377743
[TBL] [Abstract][Full Text] [Related]
5. Proteoglycans and hyaluronan in human fetal membranes.
Meinert M; Eriksen GV; Petersen AC; Helmig RB; Laurent C; Uldbjerg N; Malmström A
Am J Obstet Gynecol; 2001 Mar; 184(4):679-85. PubMed ID: 11262472
[TBL] [Abstract][Full Text] [Related]
6. Characterization and distribution of hyaluronan and the proteoglycans decorin, biglycan and perlecan in the developing embryonic mouse gonad.
Miqueloto CA; Zorn TM
J Anat; 2007 Jul; 211(1):16-25. PubMed ID: 17543016
[TBL] [Abstract][Full Text] [Related]
7. Myxomatous mitral valve chordae. II: Selective elevation of glycosaminoglycan content.
Grande-Allen KJ; Griffin BP; Calabro A; Ratliff NB; Cosgrove DM; Vesely I
J Heart Valve Dis; 2001 May; 10(3):325-32; discussion 332-3. PubMed ID: 11380095
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of the proteoglycans decorin, biglycan and versican and transforming growth factor-beta in human post-burn hypertrophic and mature scars.
Scott PG; Dodd CM; Tredget EE; Ghahary A; Rahemtulla F
Histopathology; 1995 May; 26(5):423-31. PubMed ID: 7544762
[TBL] [Abstract][Full Text] [Related]
9. The effects of mitral regurgitation alone are sufficient for leaflet remodeling.
Stephens EH; Nguyen TC; Itoh A; Ingels NB; Miller DC; Grande-Allen KJ
Circulation; 2008 Sep; 118(14 Suppl):S243-9. PubMed ID: 18824762
[TBL] [Abstract][Full Text] [Related]
10. Macrophage Transitions in Heart Valve Development and Myxomatous Valve Disease.
Hulin A; Anstine LJ; Kim AJ; Potter SJ; DeFalco T; Lincoln J; Yutzey KE
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):636-644. PubMed ID: 29348122
[TBL] [Abstract][Full Text] [Related]
11. Tgfβ-Smad and MAPK signaling mediate scleraxis and proteoglycan expression in heart valves.
Barnette DN; Hulin A; Ahmed AS; Colige AC; Azhar M; Lincoln J
J Mol Cell Cardiol; 2013 Dec; 65():137-46. PubMed ID: 24157418
[TBL] [Abstract][Full Text] [Related]
12. Proteoglycan deposition in pulmonary fibrosis.
Bensadoun ES; Burke AK; Hogg JC; Roberts CR
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1819-28. PubMed ID: 8970376
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease.
Garcia-Pena A; Ibarrola J; Navarro A; Sadaba A; Tiraplegui C; Garaikoetxea M; Arrieta V; Matilla L; Fernández-Celis A; Sadaba R; Alvarez V; Gainza A; Jover E; López-Andrés N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669101
[TBL] [Abstract][Full Text] [Related]
14. Comparative Histopathological Analysis of Mitral Valves in Barlow Disease and Fibroelastic Deficiency.
Hjortnaes J; Keegan J; Bruneval P; Schwartz E; Schoen FJ; Carpentier A; Levine RA; Hagège A; Aikawa E
Semin Thorac Cardiovasc Surg; 2016 Winter; 28(4):757-767. PubMed ID: 28417861
[TBL] [Abstract][Full Text] [Related]
15. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.
Rabkin E; Aikawa M; Stone JR; Fukumoto Y; Libby P; Schoen FJ
Circulation; 2001 Nov; 104(21):2525-32. PubMed ID: 11714645
[TBL] [Abstract][Full Text] [Related]
16. Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations.
Grande-Allen KJ; Griffin BP; Ratliff NB; Cosgrove DM; Vesely I
J Am Coll Cardiol; 2003 Jul; 42(2):271-7. PubMed ID: 12875763
[TBL] [Abstract][Full Text] [Related]
17. Structural and cellular changes in canine myxomatous mitral valve disease: an image analysis study.
Han RI; Black A; Culshaw G; French AT; Corcoran BM
J Heart Valve Dis; 2010 Jan; 19(1):60-70. PubMed ID: 20329491
[TBL] [Abstract][Full Text] [Related]
18. Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: correlation to patency.
Merrilees MJ; Beaumont B; Scott LJ
Coron Artery Dis; 2001 Feb; 12(1):7-16. PubMed ID: 11211169
[TBL] [Abstract][Full Text] [Related]
19. Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: Relevance to an age-specific tissue-engineered heart valve.
Stephens EH; Chu CK; Grande-Allen KJ
Acta Biomater; 2008 Sep; 4(5):1148-60. PubMed ID: 18448399
[TBL] [Abstract][Full Text] [Related]
20. Unravelling the proteome of degenerative human mitral valves.
Tan HT; Lim TK; Richards AM; Kofidis T; Teoh KL; Ling LH; Chung MC
Proteomics; 2015 Sep; 15(17):2934-44. PubMed ID: 25914152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
